s6y

Ernexa Therapeutics Inc.

Ticker
ERNA, ERNAW
CIK
748592
Industry
Pharmaceutical Preparations
Formerly
Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC

Financials 164

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 164 financials filings

News 352

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 352 news filings

Ownership 693

  1. 3 Initial statement of beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 3 Initial statement of beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 693 ownership filings

Prospectus 113

  1. S-3/A Registration statement for specified transactions by certain issuers
  2. S-3 Registration statement for specified transactions by certain issuers
  3. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  4. S-1/A General form of registration statement for all companies including face-amount certificate companies
  5. S-1/A General form of registration statement for all companies including face-amount certificate companies
  6. S-1 General form of registration statement for all companies including face-amount certificate companies
  7. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  8. DRSLTR Correspondence Related to Draft Registration Statement
  9. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 113 prospectus filings

Proxies 69

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEF 14C Definitive information statements
  4. PRE 14C Preliminary information statement not related to a contested matter or merger/acquisition
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEF 14A Definitive proxy statements
  8. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  9. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 69 proxies filings

Other 135

  1. SCHEDULE 13G/A
  2. SCHEDULE 13G/A
  3. SCHEDULE 13G/A
  4. SCHEDULE 13G/A
  5. SCHEDULE 13G/A
  6. SCHEDULE 13G
  7. SCHEDULE 13G
  8. SCHEDULE 13G/A
  9. ARS Annual report to security holders
  10. EFFECT Notice of Effectiveness

All 135 other filings